Navigation Links
Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) will host investors and analysts in New York City on November 18, 2010 for an in depth discussion on the current management of Clostridium difficile infection and the market opportunity for fidaxomicin.  A live webcast of the event beginning at 9:00 a.m. ET will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.

The program will feature presentations by:

  • Mark Miller, M.D., Head of Infectious Diseases Division and Chair of Infection Prevention and Control Committee, SMBD Jewish Hospital in Montreal
  • Pedro Lichtinger, President and CEO, Optimer
  • Sherwood Gorbach, M.D., Chief Medical Officer, Optimer and Professor of Public Health & Medicine, Tufts University School of Medicine

  • (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    For additional information regarding this event, please contact Christina Donaghy, Corporate Communications Manager at Optimer Pharmaceuticals, at cdonaghy@optimerpharma.com.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics that has completed two Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/19/2016)... Israel , May 19, 2016 ... the "Company"), an emerging global ophthalmic company focused on ... candidates which address ophthalmic conditions, announced today that it ... Italy ) for the manufacturing, distribution, marketing ... for the treatment of dry eye syndrome (DES) and ...
    (Date:5/19/2016)... May 19, 2016 A ... World Biopsy Devices Market Opportunities and Forecasts, 2014 ... market generated $1,621 million in 2015. The MRI-guided ... and is expected to maintain this trend over ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To know ...
    (Date:5/19/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced ... of multiple cancer and hematological indications, will be presented ... titled " Clinical response in relapsed/refractory AML patients correlates ... a potent CXCR4 antagonist; results of a Phase 2a ... the European Hematology Association 21st Congress, to be held ...
    Breaking Medicine Technology:
    (Date:5/23/2016)... ... May 23, 2016 , ... While new U.S. opioid ... physicians are not legally required to follow them. In the absence of federal ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, strongly ...
    (Date:5/23/2016)... ... ... the upcoming airing of Innovations with Ed Begley, Jr., ... 4:00pET via Fox Business. , The show will explore ... safely and rapidly develop cures for mosquito-borne, emerging infectious ...
    (Date:5/23/2016)... , ... May 23, 2016 ... ... Size for Verification and Validation:, Tools to Safely Speed Your Device to ... http://www.fdanews.com/bestdevicesamplesizevv                  , Today's FDA inspectors focus like lasers on device ...
    (Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... the action analytics leader as Chief Medical Officer. Dr. O’Connor’s deep expertise in ... product development and client services teams who deliver best-in-class solutions and transformative technologies ...
    (Date:5/23/2016)... Valley, California (PRWEB) , ... May 23, 2016 ... ... clinical communications and solutions for healthcare providers announced today that AGNITY MobileCare™ Platform ... and health collaboration applications as a part of its M-Health Solution. Tech Mahindra ...
    Breaking Medicine News(10 mins):